LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: COVID-19 and diabetes: What have we learned so far?

    Taher, Nida / Huda, Mohammed Sb / Chowdhury, Tahseen A

    Clinical medicine (London, England)

    2020  Volume 20, Issue 4, Page(s) e87–e90

    Abstract: COVID-19 and diabetes are both pandemics with major impacts on global public health ... While the response to COVID-19 has been rapid and progressive to reduce risk of harm, the response to the diabetes ... of COVID-19 on our diabetes service in an urban area in the UK. We discuss the impact on our patients and ...

    Abstract COVID-19 and diabetes are both pandemics with major impacts on global public health. While the response to COVID-19 has been rapid and progressive to reduce risk of harm, the response to the diabetes pandemic has been somewhat more muted. People with diabetes have been disproportionately affected by COVID-19, with growing evidence of higher mortality and morbidity. In this article, we discuss the impact of COVID-19 on our diabetes service in an urban area in the UK. We discuss the impact on our patients and ourselves, and the possible lessons we can carry into the future.
    MeSH term(s) Ambulatory Care/organization & administration ; Betacoronavirus ; COVID-19 ; Comorbidity ; Coronavirus Infections/epidemiology ; Diabetes Complications/epidemiology ; Diabetes Complications/therapy ; Diabetes Mellitus/epidemiology ; Diabetes Mellitus/therapy ; Hospitals, Urban ; Humans ; Hypoglycemia/epidemiology ; Hypoglycemia/therapy ; London/epidemiology ; Pandemics ; Pneumonia, Viral/epidemiology ; SARS-CoV-2 ; Telemedicine
    Keywords covid19
    Language English
    Publishing date 2020-05-22
    Publishing country England
    Document type Journal Article
    ZDB-ID 2048646-7
    ISSN 1473-4893 ; 1470-2118
    ISSN (online) 1473-4893
    ISSN 1470-2118
    DOI 10.7861/clinmed.2020-0261
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: COVID-19 and diabetes: What have we learned so far?

    Taher, Nida / Huda, Mohammed Sb / Chowdhury, Tahseen A

    Clin Med (Lond)

    Abstract: COVID-19 and diabetes are both pandemics with major impacts on global public health ... While the response to COVID-19 has been rapid and progressive to reduce risk of harm, the response to the diabetes ... of COVID-19 on our diabetes service in an urban area in the UK. We discuss the impact on our patients and ...

    Abstract COVID-19 and diabetes are both pandemics with major impacts on global public health. While the response to COVID-19 has been rapid and progressive to reduce risk of harm, the response to the diabetes pandemic has been somewhat more muted. People with diabetes have been disproportionately affected by COVID-19, with growing evidence of higher mortality and morbidity. In this article, we discuss the impact of COVID-19 on our diabetes service in an urban area in the UK. We discuss the impact on our patients and ourselves, and the possible lessons we can carry into the future.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #634091
    Database COVID19

    Kategorien

  3. Article ; Online: Diabetic ketoacidosis and COVID-19: what have we learned so far?

    de Sá-Ferreira, Caio Oliveira / da Costa, Camila Helena Macedo / Guimarães, João Campos Wiltgen / Sampaio, Nathasha Souza / Silva, Leticia de Moraes Lopes / de Mascarenhas, Larissa Paula / Rodrigues, Nicollas Garcia / Dos Santos, Talita Labonia / Campos, Solange / Young, Esther Cytrynbaum

    American journal of physiology. Endocrinology and metabolism

    2021  Volume 322, Issue 1, Page(s) E44–E53

    Abstract: ... and discoveries. It has been reported that diabetes is a risk factor for worst outcomes of COVID-19 ... with diabetes and nondiabetic patients, which may lead to fatal outcomes. DKA in patients with COVID-19 ... Ketoacidosis (Diabetic Ketoacidosis, Diabetic Acidosis, Diabetic Ketosis). There is a clear correlation between COVID-19 and DKA ...

    Abstract In December 2019, a pandemic emerged due to a new coronavirus that imposed various uncertainties and discoveries. It has been reported that diabetes is a risk factor for worst outcomes of COVID-19 and also that SARS-CoV-2 infection was correlated with the occurrence of diabetic ketoacidosis (DKA) in patients. The aim of this work is to discuss this correlation emphasizing the main case reports from 2020 while exploring the management of DKA during the course of COVID-19. Web of Science, PubMed, and Scopus databases were searched using two sets of Medical Subject Heading (MeSH) search terms or Title/Abstract words: Coronavirus Infections (Coronavirus Infections, Middle East Respiratory Syndrome, COVID-19) and Diabetic Ketoacidosis (Diabetic Ketoacidosis, Diabetic Acidosis, Diabetic Ketosis). There is a clear correlation between COVID-19 and DKA. The SARS-Cov-2 infection may precipitate both a hyperglycemic state and ketoacidosis occurrence in patients with diabetes and nondiabetic patients, which may lead to fatal outcomes. DKA in patients with COVID-19 may increase risk and worse outcomes. Hence, the SARS-Cov-2 infection presents a new perspective toward the management of glycemia and acidosis in patients with diabetes and nondiabetic patients, highlighting the need for rapid interventions to minimize the complications from COVID-19 while reducing its spreading.
    MeSH term(s) Blood Glucose/analysis ; Blood Glucose Self-Monitoring ; COVID-19/complications ; COVID-19/metabolism ; Diabetes Mellitus, Type 1/complications ; Diabetes Mellitus, Type 1/drug therapy ; Diabetes Mellitus, Type 1/metabolism ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/metabolism ; Diabetic Ketoacidosis/complications ; Diabetic Ketoacidosis/drug therapy ; Diabetic Ketoacidosis/metabolism ; Humans ; Hyperglycemia/complications ; Hyperglycemia/drug therapy ; Hypoglycemic Agents/therapeutic use ; Insulin/administration & dosage ; Insulin/therapeutic use ; Prognosis ; Risk Factors ; Telemedicine
    Chemical Substances Blood Glucose ; Hypoglycemic Agents ; Insulin
    Language English
    Publishing date 2021-11-15
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 603841-4
    ISSN 1522-1555 ; 0193-1849
    ISSN (online) 1522-1555
    ISSN 0193-1849
    DOI 10.1152/ajpendo.00244.2021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: The importance of implementing inpatient virtual coverage in an endocrinology practice: lessons learned thus far from the COVID-19 pandemic.

    Griebeler, Marcio L / Pantalone, Kevin M / Gambino, Ron / Shewmon, David / Morrow, Jay / Mendlovic, Daniel / Makin, Vinni / Hamaty, Marwan / Hasan, Sana / Lansang, M Cecilia / Zhou, Keren / Burguera, Bartolome

    Clinical diabetes and endocrinology

    2021  Volume 7, Issue 1, Page(s) 5

    Abstract: The COVID-19 pandemic has rapidly changed the landscape of medical care and the healthcare system ... in an efficient, effective, and safe manner. Endocrinology diseases are commonly present in patients with COVID-19 ... and telemedicine have already been well-established in the outpatient setting but yet not commonly ...

    Abstract The COVID-19 pandemic has rapidly changed the landscape of medical care and the healthcare system needs to quickly adapt in order to continue providing optimal medical care to hospitalized patients in an efficient, effective, and safe manner. Endocrinology diseases are commonly present in patients with COVID-19 and often are major risk factors for development of severe disease. The use of electronic consultation and telemedicine have already been well-established in the outpatient setting but yet not commonly implemented in the inpatient arena. This type of remote medical care has the potential to provide a reliable delivery of endocrine care while protecting providers and patients from spreading infection. This short review intends to provide the initial steps for the development of an inpatient telemedicine endocrine service to patients with endocrine diseases. Telehealth will become part of our daily practices and has a potential to provide a safe and efficient method of consultative service.
    Language English
    Publishing date 2021-02-09
    Publishing country England
    Document type Letter
    ZDB-ID 2834859-X
    ISSN 2055-8260
    ISSN 2055-8260
    DOI 10.1186/s40842-021-00118-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned.

    Gajendran, Mahesh / Perisetti, Abhilash / Aziz, Muhammad / Raghavapuram, Saikiran / Bansal, Pardeep / Tharian, Benjamin / Goyal, Hemant

    Annals of gastroenterology

    2020  Volume 33, Issue 6, Page(s) 591–602

    Abstract: ... Patients with severe COVID-19 are more commonly elderly and suffer from comorbidities such as hypertension ... If the patients have symptoms of COVID-19 or IBD flare-up, they are recommended to call their IBD physician first ... to minimize the chances of infection. As COVID-19 is rapidly evolving, our experience and understanding ...

    Abstract The current outbreak of COVID-19 pandemic caused by SARS-CoV-2 has affected nearly 188 countries. Patients with severe COVID-19 are more commonly elderly and suffer from comorbidities such as hypertension, diabetes mellitus, coronary artery disease, chronic pulmonary disease, obesity, and cancer. Inflammatory bowel disease (IBD) affects as many as 6.8 million people globally, and a significant proportion of them are treated with immunosuppressants. Hence, there is an ongoing concern over the impact of COVID-19 on IBD patients and their susceptibility to it. So far, there are about 1439 IBD patients in the Surveillance Epidemiology of Coronavirus under Research Exclusion (SECURE-IBD) registry reported to be infected with SARS-CoV-2. There are many unique challenges and dilemmas that need to be taken into account when managing an IBD patient with COVID-19. The management of each patient should be individualized. The IBD societies and experts have strongly recommended that patients should not discontinue their IBD medications. If the patients have symptoms of COVID-19 or IBD flare-up, they are recommended to call their IBD physician first to discuss their medication. In addition, IBD patients are urged to practice social distancing strictly to minimize the chances of infection. As COVID-19 is rapidly evolving, our experience and understanding of its impact on the IBD population may potentially change in the near future.
    Keywords covid19
    Language English
    Publishing date 2020-10-12
    Publishing country Greece
    Document type Journal Article ; Review
    ZDB-ID 2032850-3
    ISSN 1108-7471
    ISSN 1108-7471
    DOI 10.20524/aog.2020.0547
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: The 5% of the Population at High Risk for Severe COVID-19 Infection Is Identifiable and Needs to Be Taken Into Account When Reopening the Economy.

    Preskorn, Sheldon H

    Journal of psychiatric practice

    2020  Volume 26, Issue 3, Page(s) 219–227

    Abstract: ... the damage caused by COVID-19 requires that we obtain knowledge about the disease and its treatment or prevention ... since the COVID-19 virus emerged as a human pathogen have provided guidance for our decisions going forward ... The most widely adopted strategies for dealing with the COVID-19 pandemic to date have involved ...

    Abstract The goal of this column is to help mental health care professionals understand coronavirus disease 2019 (COVID-19) so that they can better explain the complexities of the current crisis to their patients. The bottom-line of this column is that, while COVID-19 can infect virtually everyone in the human population, only about 5% are susceptible to severe infection requiring admission to an intensive care unit and/or causing a fatal outcome and this population can be identified on the basis of comorbid medical illness and/or age. These numbers are based on experience in China, the United States, and Europe. Table 1 presents an analysis conducted by the US Centers for Disease Control and Prevention (CDC), which is further supported by several other sources reviewed in the article. The population at risk for severe infection are individuals with comorbid medical illness and those 85 years of age and older. The comorbid medical illnesses identified as risk factors are preexisting respiratory and cardiovascular disease, immunocompromised status, morbid obesity (ie, body mass index ≥40), diabetes mellitus, and possibly significant kidney or liver impairment. Parenthetically, news reports and the literature sometimes cite age 60 years and older as a risk factor but age between 60 and 85 years is likely a surrogate for having 1 or more of these comorbid medical conditions. While 5% may initially seem like a small number, it nevertheless potentially represents 16.5 million people, given the United States population of 330 million. That is a tremendous number of people requiring intensive care unit admission and/or potentially dying, and individuals in this population have overwhelmed the US health care system in some hotspots. For this reason, this column suggests taking this at-risk population into account in mitigation strategies when attempting to open the US economy. The column addresses the following questions: (1) What are the 3 aspects of the race to minimize the damage caused by COVID-19? (2) What data are currently available to help guide decisions to be made? (3) What strategies have been employed to date and how successful have they been? and (4) Might risk stratification of exposure be a viable strategy to minimize the damage caused by the virus? The race to minimize the damage caused by COVID-19 requires that we obtain knowledge about the disease and its treatment or prevention, how to best safeguard public health and avoid overwhelming the health care system, and how to minimize the societal damage caused by substantial disruption of the economy. Data gathered over the past 4 months since the COVID-19 virus emerged as a human pathogen have provided guidance for our decisions going forward. The most widely adopted strategies for dealing with the COVID-19 pandemic to date have involved the epidemiological approach of encouraging good hygiene practices and social distancing, including orders to "shelter in place," quarantine of high-risk individuals, and isolation of infected individuals. The goal of this epidemiological approach has been to "flatten the curve" by reducing the height of the peak of the infection to avoid overwhelming the health care system and society in general, while buying time to learn more about the disease and find more effective ways to deal with it. However, now that more is known about COVID-19 and the portion of the population that is most at risk for serious adverse outcomes including death, it may be possible to move from a shelter-in-place approach for the entire population to focus on those at most risk and thus facilitate a gradual and rational phased reduction of social restrictions to reopen the economy. Such a graduated opening would be based on regions of countries meeting specific criteria in terms of being able to contain the virus, coupled with vigorous monitoring to look for outbreaks, followed by case monitoring, isolation of infected individuals and quarantine of exposed individuals, and increased use of testing for active disease as well as for immunity. Taking the data on high-risk individuals into account would allow for a gradual lifting of restrictions on the majority of the population while maintaining more stringent safeguards to protect the vulnerable portion of the population. Nevertheless, the entire population would need to continue to practice good hygiene and social distancing while simultaneously-and perhaps even more vigorously-focusing on sheltering the vulnerable population until adequate community immunity has been achieved to prevent the spread of the virus, whether that is accomplished through natural exposure alone or with the addition of safe and effective vaccine(s) which may not be available for a year. Continued widespread testing for antibodies will help determine how far or close this country is-and other countries are-from developing effective community immunity.
    MeSH term(s) Aged ; Aged, 80 and over ; Betacoronavirus ; COVID-19 ; China/epidemiology ; Commerce ; Comorbidity ; Coronavirus Infections/epidemiology ; Coronavirus Infections/prevention & control ; Coronavirus Infections/transmission ; Delivery of Health Care ; Economics ; Humans ; Infection Control ; Middle Aged ; Pandemics/prevention & control ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/prevention & control ; Pneumonia, Viral/transmission ; Public Health ; Public Policy ; Quarantine ; Risk Assessment ; SARS-CoV-2 ; Severity of Illness Index ; United States/epidemiology
    Keywords covid19
    Language English
    Publishing date 2020-11-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2022726-7
    ISSN 1538-1145 ; 1527-4160
    ISSN (online) 1538-1145
    ISSN 1527-4160
    DOI 10.1097/PRA.0000000000000475
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned

    Gajendran, M. / Perisetti, A. / Aziz, M. / Raghavapuram, S. / Bansal, P. / Tharian, B. / Goyal, H.

    Annals of Gastroenterology

    Abstract: ... Patients with severe COVID-19 are more commonly elderly and suffer from comorbidities such as hypertension ... If the patients have symptoms of COVID-19 or IBD flare-up, they are recommended to call their IBD physician first ... to minimize the chances of infection As COVID-19 is rapidly evolving, our experience and understanding ...

    Abstract The current outbreak of COVID-19 pandemic caused by SARS-CoV-2 has affected nearly 188 countries Patients with severe COVID-19 are more commonly elderly and suffer from comorbidities such as hypertension, diabetes mellitus, coronary artery disease, chronic pulmonary disease, obesity, and cancer Inflammatory bowel disease (IBD) affects as many as 6 8 million people globally, and a significant proportion of them are treated with immunosuppressants Hence, there is an ongoing concern over the impact of COVID-19 on IBD patients and their susceptibility to it So far, there are about 1439 IBD patients in the Surveillance Epidemiology of Coronavirus under Research Exclusion (SECURE-IBD) registry reported to be infected with SARS-CoV-2 There are many unique challenges and dilemmas that need to be taken into account when managing an IBD patient with COVID-19 The management of each patient should be individualized The IBD societies and experts have strongly recommended that patients should not discontinue their IBD medications If the patients have symptoms of COVID-19 or IBD flare-up, they are recommended to call their IBD physician first to discuss their medication In addition, IBD patients are urged to practice social distancing strictly to minimize the chances of infection As COVID-19 is rapidly evolving, our experience and understanding of its impact on the IBD population may potentially change in the near future
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #916608
    Database COVID19

    Kategorien

  8. Article: The 5% of the Population at High Risk for Severe COVID-19 Infection Is Identifiable and Needs to Be Taken Into Account When Reopening the Economy

    Preskorn, Sheldon H

    J Psychiatr Pract

    Abstract: ... the damage caused by COVID-19 requires that we obtain knowledge about the disease and its treatment or prevention ... since the COVID-19 virus emerged as a human pathogen have provided guidance for our decisions going forward ... The most widely adopted strategies for dealing with the COVID-19 pandemic to date have involved ...

    Abstract The goal of this column is to help mental health care professionals understand coronavirus disease 2019 (COVID-19) so that they can better explain the complexities of the current crisis to their patients. The bottom-line of this column is that, while COVID-19 can infect virtually everyone in the human population, only about 5% are susceptible to severe infection requiring admission to an intensive care unit and/or causing a fatal outcome and this population can be identified on the basis of comorbid medical illness and/or age. These numbers are based on experience in China, the United States, and Europe. Table 1 presents an analysis conducted by the US Centers for Disease Control and Prevention (CDC), which is further supported by several other sources reviewed in the article. The population at risk for severe infection are individuals with comorbid medical illness and those 85 years of age and older. The comorbid medical illnesses identified as risk factors are preexisting respiratory and cardiovascular disease, immunocompromised status, morbid obesity (ie, body mass index ≥40), diabetes mellitus, and possibly significant kidney or liver impairment. Parenthetically, news reports and the literature sometimes cite age 60 years and older as a risk factor but age between 60 and 85 years is likely a surrogate for having 1 or more of these comorbid medical conditions. While 5% may initially seem like a small number, it nevertheless potentially represents 16.5 million people, given the United States population of 330 million. That is a tremendous number of people requiring intensive care unit admission and/or potentially dying, and individuals in this population have overwhelmed the US health care system in some hotspots. For this reason, this column suggests taking this at-risk population into account in mitigation strategies when attempting to open the US economy. The column addresses the following questions: (1) What are the 3 aspects of the race to minimize the damage caused by COVID-19? (2) What data are currently available to help guide decisions to be made? (3) What strategies have been employed to date and how successful have they been? and (4) Might risk stratification of exposure be a viable strategy to minimize the damage caused by the virus? The race to minimize the damage caused by COVID-19 requires that we obtain knowledge about the disease and its treatment or prevention, how to best safeguard public health and avoid overwhelming the health care system, and how to minimize the societal damage caused by substantial disruption of the economy. Data gathered over the past 4 months since the COVID-19 virus emerged as a human pathogen have provided guidance for our decisions going forward. The most widely adopted strategies for dealing with the COVID-19 pandemic to date have involved the epidemiological approach of encouraging good hygiene practices and social distancing, including orders to "shelter in place," quarantine of high-risk individuals, and isolation of infected individuals. The goal of this epidemiological approach has been to "flatten the curve" by reducing the height of the peak of the infection to avoid overwhelming the health care system and society in general, while buying time to learn more about the disease and find more effective ways to deal with it. However, now that more is known about COVID-19 and the portion of the population that is most at risk for serious adverse outcomes including death, it may be possible to move from a shelter-in-place approach for the entire population to focus on those at most risk and thus facilitate a gradual and rational phased reduction of social restrictions to reopen the economy. Such a graduated opening would be based on regions of countries meeting specific criteria in terms of being able to contain the virus, coupled with vigorous monitoring to look for outbreaks, followed by case monitoring, isolation of infected individuals and quarantine of exposed individuals, and increased use of testing for active disease as well as for immunity. Taking the data on high-risk individuals into account would allow for a gradual lifting of restrictions on the majority of the population while maintaining more stringent safeguards to protect the vulnerable portion of the population. Nevertheless, the entire population would need to continue to practice good hygiene and social distancing while simultaneously-and perhaps even more vigorously-focusing on sheltering the vulnerable population until adequate community immunity has been achieved to prevent the spread of the virus, whether that is accomplished through natural exposure alone or with the addition of safe and effective vaccine(s) which may not be available for a year. Continued widespread testing for antibodies will help determine how far or close this country is-and other countries are-from developing effective community immunity.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #32421292
    Database COVID19

    Kategorien

To top